LPL Financial LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,321 shares of the company's stock, valued at approximately $251,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after purchasing an additional 918 shares during the period. Caitlin John LLC lifted its stake in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Pacira BioSciences by 17.4% in the 4th quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company's stock worth $258,000 after purchasing an additional 2,034 shares during the period. Finally, Global Alpha Capital Management Ltd. increased its position in shares of Pacira BioSciences by 5.7% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company's stock valued at $752,000 after purchasing an additional 2,160 shares during the last quarter. 99.73% of the stock is owned by institutional investors.
Pacira BioSciences Trading Down 1.6 %
Shares of Pacira BioSciences stock traded down $0.43 on Friday, hitting $26.33. 247,270 shares of the company traded hands, compared to its average volume of 983,159. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a market cap of $1.22 billion, a PE ratio of -12.96 and a beta of 0.71. The stock's 50 day moving average price is $24.61 and its 200-day moving average price is $21.75. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. HC Wainwright raised their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Pacira BioSciences in a research note on Tuesday, April 8th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their price objective for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada reissued a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays upped their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $26.67.
Read Our Latest Report on PCRX
Pacira BioSciences Company Profile
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Stories
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
